Rodent Models of CVD

Unique, highly translatable models of CVD, paired with industry
standard and inducible models


Need to Correlate with Historic Data or Ready to Move to the Next Level Translational Models?

At CrownBio we understand the need for consistency within client cardiovascular disease (CVD) research. We therefore provide all conventional, commercially available rodent models for CVD studies to fit our client’s needs. These in vivo CVD resources are complemented by experimentally induced disease models such as:

  • Uni-nephrectomized Sprague-Dawley (SD) rats receiving aldosterone and salt in their drinking water which develop hypertension

Eplerenone Reduces Blood Pressure in Uni-Nephrectomized Male, Sprague-Dawley Rats as Monitored by Continuous Telemetry: Daily Telemetric Averages

Unique Preclinical Rodent CVD Models with Hypertension

CrownBio also provides our proprietary, highly translatable ZDSD rat model of CVD, which naturally develops high blood pressure on a normal chow diet, providing a suitable model for CVD research and antihypertensive evaluation.

The ZDSD rat is a polygenic model of dysmetabolism with a functional leptin/leptin receptor pathway. ZDSD rats present CVD specific features such as:

  • Elevated biomarkers for an activated renin–angiotensin–aldosterone system (RAAS)
  • Endothelial dysfunction
  • Aberrant vasoconstriction
  • Hypertension (in the prediabetic state) confirmed via the tail-cuff method and telemetry.

Monitor Key CVD Endpoints Including Continuous BP Measurement

CrownBio provides two key technologies for CVD studies in our rodent models: measurement of blood pressure (BP) and platelet aggregometry.

BP can be measured in our rat or mouse models via:

  • Tail-cuff technology for a rapid, non-invasive BP read
  • Radio telemetry providing continuous BP measurement for a higher definition BP evaluation, including mean arterial pressure (MAP), systolic and diastolic pressures, and heart rate, over several months if needed.

CrownBio also provides platelet aggregometry assessment, to evaluate the effects of novel compounds on platelet function.

Discuss Your Cardiovascular Project